Predictive Model for Long COVID in Children 3 Months After a SARS-CoV-2 PCR Test
Overview
Authors
Affiliations
Background: To update and internally validate a model to predict children and young people (CYP) most likely to experience long COVID (i.e. at least one impairing symptom) 3 months after SARS-CoV-2 PCR testing and to determine whether the impact of predictors differed by SARS-CoV-2 status.
Methods: Data from a nationally matched cohort of SARS-CoV-2 test-positive and test-negative CYP aged 11-17 years was used. The main outcome measure, long COVID, was defined as one or more impairing symptoms 3 months after PCR testing. Potential pre-specified predictors included SARS-CoV-2 status, sex, age, ethnicity, deprivation, quality of life/functioning (five EQ-5D-Y items), physical and mental health and loneliness (prior to testing) and number of symptoms at testing. The model was developed using logistic regression; performance was assessed using calibration and discrimination measures; internal validation was performed via bootstrapping and the final model was adjusted for overfitting.
Results: A total of 7139 (3246 test-positives, 3893 test-negatives) completing a questionnaire 3 months post-test were included. 25.2% (817/3246) of SARS-CoV-2 PCR-positives and 18.5% (719/3893) of SARS-CoV-2 PCR-negatives had one or more impairing symptoms 3 months post-test. The final model contained SARS-CoV-2 status, number of symptoms at testing, sex, age, ethnicity, physical and mental health, loneliness and four EQ-5D-Y items before testing. Internal validation showed minimal overfitting with excellent calibration and discrimination measures (optimism-adjusted calibration slope: 0.96575; C-statistic: 0.83130).
Conclusions: We updated a risk prediction equation to identify those most at risk of long COVID 3 months after a SARS-CoV-2 PCR test which could serve as a useful triage and management tool for CYP during the ongoing pandemic. External validation is required before large-scale implementation.
Khanna D, Lay K, Khadka J, Mpundu-Kaambwa C, Ratcliffe J Health Qual Life Outcomes. 2024; 22(1):105.
PMID: 39633400 PMC: 11619400. DOI: 10.1186/s12955-024-02320-4.
Nugawela M, Stephenson T, Shafran R, Chalder T, Dalrymple E, Ford T BMC Med. 2024; 22(1):520.
PMID: 39511637 PMC: 11545583. DOI: 10.1186/s12916-024-03708-1.
Hsu Y, Chen P, Tsai Y, Wei C, Wu L, Hsieh K Vaccines (Basel). 2024; 12(8).
PMID: 39204035 PMC: 11359259. DOI: 10.3390/vaccines12080910.
Long COVID in Children and Adolescents: A Critical Review.
Rothensteiner M, Leeb F, Gotzinger F, Tebruegge M, Zacharasiewicz A Children (Basel). 2024; 11(8).
PMID: 39201907 PMC: 11352730. DOI: 10.3390/children11080972.
Pinto Pereira S, Nugawela M, Stephenson T, Foret-Bruno P, Dalrymple E, Xu L Sci Rep. 2024; 14(1):9957.
PMID: 38693285 PMC: 11063180. DOI: 10.1038/s41598-024-60372-4.